NCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
Clinical Trials
9 trialsNCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT00770848 2014-03-10
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Amgen
Phase 1/2 Completed
NCT00004071 2012-09-11
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Pfizer
Phase 2/3 Completed
NCT00003343 2012-08-08
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
Pfizer
Phase 3 Completed
NCT00436839 2012-07-09
Taxotere Prostate Cancer New Indication Registration Trial in China
Sanofi
Phase 3 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed